Added to YB: 2026-09-15
Pitch date: 2026-09-11
ADCT [neutral]
ADC Therapeutics SA
+3.74%
current return
Author Info
No bio for this author
Company Info
ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States.
Market Cap
$136.6M
Pitch Price
$1.07
Price Target
N/A
Dividend
N/A
EV/EBITDA
-3.83
P/E
-1.65
EV/Sales
4.47
Sector
Biotechnology
Category
turnaround
Biotech Conference coverage day 4 session 1 - ADC Therapeutics SA
ADCT (quick overview): ADC Therapeutics is trying to turn the $75-80M third-line DLBCL drug Zynlonta into a broader lymphoma franchise. The November LOTUS7 dataset is pivotal after the initial 49 patients showed a 78% complete-response rate with Zynlonta-glofitamab. At roughly $1.09, upside could be significant if responses prove durable and infection risk manageable, but LOTUS5’s Grade 5-event imbalance leaves a major FDA benefit-risk overhang.
Read full article (2 min)